Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Summary

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Eligibility

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
* HLA-A\*02:01-positive
* Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma
* Archived or fresh tumor tissue sample that must be confirmed as adequate
* Evaluable/Measurable disease per RECIST 1.1
* Previously received applicable standard treatments
* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control

Exclusion Criteria:

* Symptomatic or untreated central nervous system metastasis
* Recent bowel obstruction
* Ongoing ascites or effusion requiring recent drainages
* Significant ongoing toxicity from prior anticancer treatment
* Out-of-range laboratory values
* Clinically significant lung, heart, or autoimmune disease
* Ongoing requirement for immunosuppressive treatment
* Significant secondary malignancy
* Hypersensitivity to study drug or excipients
* Pregnant or lactating

Conditions2

Interventions5

Related trials

• CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
• Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer — Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
• Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting — University Hospital, Strasbourg, France
• DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases — Tehran University of Medical Sciences
• Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars — University Hospital, Linkoeping
• MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. — National Cancer Institute, Naples
• Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer — Chinese PLA General Hospital
• Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not — First Affiliated Hospital of Zhejiang University

Browse More Trials